WuXi Biologics (Cayman) revenue and financials
$56.70Change from previous close: −2.07%Absolute change: −$1.20
In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +16.68%
- 2025 vs 2024
- Net income growth
- +46.25%
- 2025 vs 2024
- Net margin
- 22.5%
- 2024: 18.0%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 21,790 | 18,675 | 17,034 | 15,269 | 10,290 |
| Cost of revenue | 11,772 | 11,025 | 10,206 | 8,545 | 5,461 |
| Gross profit | 10,019 | 7,651 | 6,828 | 6,724 | 4,829 |
| Selling, general and administrative | 2,313 | 2,147 | 1,789 | 1,433 | 1,001 |
| Research and development | 853 | 766 | 786 | 683 | 502 |
| Operating income | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 |
| EBIT | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 |
| EBITDA | 7,925 | 5,849 | 4,928 | 5,069 | 3,622 |
| Interest expense | 143 | 158 | 158 | 64.4 | 39.2 |
| Pre-tax income | 7,257 | 4,834 | 4,174 | 5,358 | 3,993 |
| Income tax | 1,524 | 889 | 603 | 808 | 485 |
| Net income | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
| Net income to common shareholders | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
| Basic EPS | 1.22 | 0.82 | 0.82 | 1.06 | 0.81 |
| Diluted EPS | 1.16 | 0.78 | 0.77 | 1.01 | 0.77 |
| Average shares (basic) | 4,027 | 4,082 | 4,164 | 4,173 | 4,174 |
| Average shares (diluted) | 4,176 | 4,227 | 4,349 | 4,376 | 4,422 |